Catalyst Calendar

Mon, Jun 22, 2026

1 updates

8:00 AM

Exelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer

ALAMEDA, Calif. --(BUSINESS WIRE)--Jun. 22, 2026-- Exelixis, Inc. (Nasdaq: EXEL) today announced results from the final analysis of the dual primary endpoint of overall survival ( OS) in the subset of patients without active liver metastases (non-liver metastases, NLM) in the phase 3 STELLAR-303

Trial Results • Phase 3STELLAR-303 NLM subgroup OS results Mon, Jun 22, 2026exelixis.com

Sat, May 30, 2026

1 updates

EXEL

10:00 AM

Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026

– CABOMETYX significantly reduced the risk of disease progression or death by 74% and 60% in patients with non-functional and functional advanced NET, respectively, versus placebo – ALAMEDA, Calif. --(BUSINESS WIRE)--May 30, 2026-- Exelixis, Inc. (Nasdaq: EXEL) today announced results from a

Presentation / Abstract • Phase 3ASCO presentation Fri, May 29, 2026exelixis.com

Wed, May 27, 2026

1 updates

EXEL

4:05 PM

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in June

- Presentations to be webcast on www.exelixis.com - ALAMEDA, Calif. --(BUSINESS WIRE)--May 27, 2026-- Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in June: 2026 Jefferies Global Healthcare Conference:

exelixis.com

Thu, May 21, 2026

1 updates

EXEL

5:00 PM

Exelixis Announces Presentations at ASCO 2026 Highlighting Ongoing Studies in Diverse Tumor Types

– Findings in neuroendocrine tumors, kidney cancer, advanced colorectal cancer and other tumors to be presented – ALAMEDA, Calif. --(BUSINESS WIRE)--May 21, 2026-- Exelixis, Inc. (Nasdaq: EXEL) today announced presentations for its flagship product, CABOMETYX ® (cabozantinib), and its

Presentation / Abstract • Phase 3ASCO oral presentation Fri, May 29, 2026, 2:45 PM CDTexelixis.com

Tue, May 19, 2026

1 updates

EXEL

8:00 AM

Exelixis Announces Clinical Development Collaboration with Merck for Phase 3 STELLAR-316 Pivotal Trial for Patients with Colorectal Cancer

– Merck to supply KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), the company’s subcutaneous anti-PD-1 therapy, for planned STELLAR-316 trial – ALAMEDA, Calif. --(BUSINESS WIRE)--May 19, 2026-- Exelixis, Inc. (Nasdaq: EXEL) today announced that the company has entered into a

exelixis.com

Thu, May 7, 2026

1 updates

EXEL

4:05 PM

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May

- Presentations to be webcast on www.exelixis.com - ALAMEDA, Calif. --(BUSINESS WIRE)--May 7, 2026-- Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in May: BofA Securities Health Care Conference 2026:

exelixis.com

Tue, May 5, 2026

1 updates

EXEL

4:05 PM

Exelixis Announces First Quarter 2026 Financial Results and Provides Corporate Update

- Total Revenues of $610.8 million, Cabozantinib Franchise U.S. Net Product Revenues of $555.0 million - - GAAP Diluted EPS of $0.79, Non-GAAP Diluted EPS of $0.87 - - Announced Additional Stock Repurchase Program for up to $750 million by the End of 2027 - - Conference Call and Webcast Today

exelixis.com

Tue, Apr 21, 2026

1 updates

EXEL

4:05 PM

Exelixis to Release First Quarter 2026 Financial Results on Tuesday, May 5, 2026

– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – ALAMEDA, Calif. --(BUSINESS WIRE)--Apr. 21, 2026-- Exelixis, Inc. (Nasdaq: EXEL) announced today that its first quarter 2026 financial results will be released on Tuesday, May 5, 2026 after the markets close. At 5:00 p.m.

exelixis.com